Product Details
Source
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122) (SCT-M369), originally from mouse immunized with recombinant SARS-CoV-2 Spike RBD protein, is recombinantly expressed from HEK293 cells.
Clone
AM122
Species
Mouse
Isotype
Mouse IgG1 | Mouse Kappa
Conjugate
Unconjugated
Antibody Type
Recombinant Monoclonal
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. Cross-reactivity with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1 has not been tested.
Application
ApplicationRecommended UsageELISA0.8-100 ng/mLPurity
95% as determined by SDS-PAGE.
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA

Immobilized SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (Cat. No. SPN-C52Hz) at 2μg/mL (100μL/well) can bind Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122) (Cat. No. SCT-M369) with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















